Akash Pawar1, Oindrila Roy Chowdhury1, Ruby Chauhan1, Sanjay Talole1,2, Atanu Bhattacharjee3,4. 1. Section of Biostatistics, Center for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India. 2. Homi Bhabha National Institute, Mumbai, India. 3. Section of Biostatistics, Center for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India. atanustat@gmail.com. 4. Homi Bhabha National Institute, Mumbai, India. atanustat@gmail.com.
Abstract
BACKGROUND: The five-year overall survival (OS) of advanced-stage ovarian cancer remains nearly 25-35%, although several treatment strategies have evolved to get better outcomes. A considerable amount of heterogeneity and complexity has been seen in ovarian cancer. This study aimed to establish gene signatures that can be used in better prognosis through risk prediction outcome for the survival of ovarian cancer patients. Different studies' heterogeneity into a single platform is presented to explore the penetrating genes for poor or better survival. The integrative analysis of multiple data sets was done to determine the genes that influence poor or better survival. A total of 6 independent data sets was considered. The Cox Proportional Hazard model was used to obtain significant genes that had an impact on ovarian cancer patients. The gene signatures were prepared by splitting the over-expressed and under-expressed genes parallelly by the variable selection technique. The data visualisation techniques were prepared to predict the overall survival, and it could support the therapeutic regime. RESULTS: We preferred to select 20 genes in each data set as upregulated and downregulated. Irrespective of the selection of multiple genes, not even a single gene was found common among data sets for the survival of ovarian cancer patients. However, the same analytical approach adopted. The chord plot was presented to make a comprehensive understanding of the outcome. CONCLUSIONS: This study helps us to understand the results obtained from different studies. It shows the impact of the heterogeneity from one study to another. It shows the requirement of integrated studies to make a holistic view of the gene signature for ovarian cancer survival.
BACKGROUND: The five-year overall survival (OS) of advanced-stage ovarian cancer remains nearly 25-35%, although several treatment strategies have evolved to get better outcomes. A considerable amount of heterogeneity and complexity has been seen in ovarian cancer. This study aimed to establish gene signatures that can be used in better prognosis through risk prediction outcome for the survival of ovarian cancer patients. Different studies' heterogeneity into a single platform is presented to explore the penetrating genes for poor or better survival. The integrative analysis of multiple data sets was done to determine the genes that influence poor or better survival. A total of 6 independent data sets was considered. The Cox Proportional Hazard model was used to obtain significant genes that had an impact on ovarian cancer patients. The gene signatures were prepared by splitting the over-expressed and under-expressed genes parallelly by the variable selection technique. The data visualisation techniques were prepared to predict the overall survival, and it could support the therapeutic regime. RESULTS: We preferred to select 20 genes in each data set as upregulated and downregulated. Irrespective of the selection of multiple genes, not even a single gene was found common among data sets for the survival of ovarian cancer patients. However, the same analytical approach adopted. The chord plot was presented to make a comprehensive understanding of the outcome. CONCLUSIONS: This study helps us to understand the results obtained from different studies. It shows the impact of the heterogeneity from one study to another. It shows the requirement of integrated studies to make a holistic view of the gene signature for ovarian cancer survival.
Authors: Asta Försti; Qianren Jin; Andrea Altieri; Robert Johansson; Kerstin Wagner; Kerstin Enquist; Ewa Grzybowska; Jolanta Pamula; Wioletta Pekala; Göran Hallmans; Per Lenner; Kari Hemminki Journal: Breast Cancer Res Treat Date: 2006-06-29 Impact factor: 4.872
Authors: Lara Lusa; Lisa M McShane; James F Reid; Loris De Cecco; Federico Ambrogi; Elia Biganzoli; Manuela Gariboldi; Marco A Pierotti Journal: J Natl Cancer Inst Date: 2007-11-13 Impact factor: 13.506
Authors: Amir A Jazaeri; Cindy J Yee; Christos Sotiriou; Kelly R Brantley; Jeff Boyd; Edison T Liu Journal: J Natl Cancer Inst Date: 2002-07-03 Impact factor: 13.506